Noida-based startup Redcliffe Labs plans to invest further $10 million towards the expansion of its genetic and specialised testing portfolio.

The company, which has a focus on next generation technologies in the diagnostics space after building artificial intelligence (AI) platform, has already invested $6 million into genetics and specialised testing coverage from Prenatal to Oncology, Neurology, Nephrology, Gut Microbiome and the fastest growing Pharmacogenomics.

“We plan to add advanced high throughput NGS facilities at our expanded NRL site and de-centralised low throughput sequencers across all Regional Reference labs. This will bring the fastest TAT to our clinicians and truly build affordable genomics. The technology choices are governed by main factors like reducing sequencing cost and innovation led by market leaders like Illumina, ThermoFisher, Oxford Nanapore, etc. We have also restructured our KOL national teams and integrated our specialised focus with routine teams bringing additional efficiencies on the new scale. We have also increased our offering, with a very large in-house team serving clinicians everyday across 100+ cities giving them access to genetic counselling, research projects and deeper clinical insights on each report” says Dheeraj Jain, Founder & MD, Redcliffe Labs.

Redcliffe Labs at present has 43+ labs and 1100+ authorised collection centres, and it is working towards building additional 57 labs in next 6 months, 1200 collection centres, and be accessible in more than 200 cities and 3500 pin-codes by June’23.